Antibody-Drug Conjugates in Cancer Treatment

A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).

The expert panel discusses the history of antibody-drug conjugates and explores their mechanisms of action.

A breast medical oncologist and nurse practitioner review molecular testing practices for patients with breast cancer.

Comprehensive insights on biomarker testing practices for patients with lung or gastrointestinal cancers.

Medical oncologists review the complexities of molecular testing, including tissue exhaustion, and discuss management approaches.

The expert panel has a comprehensive discussion about best practices for patient education and the barriers to effective testing.

A breast medical oncologist provides insights on antibody-drug conjugates in the breast cancer space and discusses ongoing research.

Specialists in breast cancer review toxicity management practices for T-DM1 and trastuzumab deruxtecan [T-DXd].

A medical oncologist reviews the antibody-drug conjugate landscape in lung cancer.

A nurse practitioner provides insights on toxicity management strategies for patients with lung cancer who are receiving antibody-drug conjugates.

A GI medical oncologist discusses the role of trastuzumab deruxtecan in the gastric cancer treatment space.

Insights on managing antibody-drug conjugate toxicities for patients with gastric cancer.

A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.

The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.

Clinical insights on best practices for treating patients with TROP2-targeted therapy.

Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.

Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.

Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.

The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.